RXO, Inc. Form 8-K Summary
Business Context and Reporting Period
RXO, Inc. filed a Form 8-K dated April 11, 2024, reporting entry into Amendment No. 2 to its revolving credit agreement. The filing does not report quarterly operating results or establish a new financial reporting period.
Material Agreement and Financial Terms
- The amendment increases the consolidated leverage ratio covenant under the revolving credit facility during a defined Covenant Relief Period.
- The revised covenant thresholds are 4.25:1.00 for the quarters ending June 30 and September 30, 2024; 4.00:1.00 for the quarter ending December 31, 2024; and 3.75:1.00 for the quarter ending March 31, 2025.
- The covenant returns to 3.50:1.00 beginning with the quarter ending June 30, 2025.
- The filing does not provide the facility’s total commitment, outstanding borrowings, interest rate, liquidity balance, or current consolidated leverage ratio.
Material Changes, Restrictions, and Outlook
- During the Covenant Relief Period, RXO and its subsidiaries are subject to restrictions on dividends and other equity distributions, share repurchases, other restricted payments, and certain material acquisitions, subject to specified exceptions.
- RXO may elect to terminate the Covenant Relief Period and related restrictions if its applicable consolidated leverage ratio is not greater than 3.50:1.00 at a fiscal quarter end.
- The amendment indicates a need for temporary covenant relief but does not state that a covenant breach has occurred.
- The filing provides no revenue, profit, cash flow, margin, debt balance, liquidity, earnings guidance, or broader management outlook.
Investor Verification Items
- Review Exhibit 10.1 for the complete amendment, including exceptions, definitions, lender rights, and other conditions.
- Verify RXO’s reported leverage ratio, debt maturities, revolver availability, and compliance with the amended covenant in subsequent filings.
- Assess the practical impact of restrictions on capital allocation, share repurchases, dividends, acquisitions, and other restricted payments.
- Confirm whether RXO elects to terminate the Covenant Relief Period before March 31, 2025, and whether the 3.50:1.00 covenant is restored as scheduled on June 30, 2025.